

LYMPHOID NEOPLASIA

CME Article

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Alyssa Bouska,^{1,*} Chengfeng Bi,^{1,*} Waseem Lone,^{1,*} Weiwei Zhang,¹ Ambreen Kedwaii,¹ Tayla Heavican,¹ Cynthia M. Lachel,² Jiayu Yu,¹ Roberto Ferro,² Nanees Eldorhamy,¹ Timothy C. Greiner,¹ Julie Vose,² Dennis D. Weisenburger,³ Randy D. Gascoyne,⁴ Andreas Rosenwald,⁵ German Ott,⁶ Elias Campo,⁷ Lisa M. Rimsza,⁸ Elaine S. Jaffe,⁹ Rita M. Braziel,¹⁰ Reiner Siebert,¹¹ Rodney R. Miles,¹² Sandeep Dave,¹³ Anupama Reddy,¹³ Jan Delabie,¹⁴ Louis M. Staudt,¹⁵ Joo Y. Song,³ Timothy W. McKeithan,³ Kai Fu,¹ Michael Green,^{16,17} Wing C. Chan,^{3,†} and Javeed Iqbal^{1,†}

¹Pathology and Microbiology and ²Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE; ³Department of Pathology, City of Hope National Medical Center, Duarte, CA; ⁴Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada; ⁵Department of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; ⁶Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; ⁷Hematopathology Unit, Hospital Clinic, Barcelona, Spain; ⁸Department of Pathology, University of Arizona, Tucson, AZ; ⁹Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; ¹⁰Oregon Health Sciences Center, Portland, OR; ¹¹Institute of Human Genetics, University Hospital of Ulm, Ulm, Germany; ¹²Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT; ¹³Institute of Genome Sciences and Department of Medicine, Duke University Medical Center, Durham, NC; ¹⁴Department of Pathology, University of Toronto, Toronto, ON, Canada; ¹⁵Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; ¹⁶Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE; and ¹⁷Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX

Key Points

- Adult-mBLs have distinct and more frequent DNA copy number abnormalities compared with pediatric-mBL.
- Comprehensive genomic analysis revealed that the BCR signaling pathway is a potential therapeutic target in adult-mBL.

The adult high-grade B-cell lymphomas sharing molecular features with Burkitt lymphoma (BL) are highly aggressive lymphomas with poor clinical outcome. High-resolution structural and functional genomic analysis of adult Burkitt lymphoma (BL) and high-grade B-cell lymphoma with BL gene signature (adult-molecularly defined BL [mBL]) revealed the MYC-ARF-p53 axis as the primary deregulated pathway. Adult-mBL had either unique or more frequent genomic aberrations (del13q14, del17p, gain8q24, and gain18q21) compared with pediatric-mBL, but shared commonly mutated genes. Mutations in genes promoting the tonic B-cell receptor (BCR)→PI3K pathway (*TCF3* and *ID3*) did not differ by age, whereas effectors of chronic BCR→NF-κB signaling were associated with adult-mBL. A subset of adult-mBL had *BCL2* translocation and mutation and elevated *BCL2* mRNA and protein expression, but had a mutation profile similar to mBL. These double-hit lymphomas may have arisen from a tumor precursor that acquired both *BCL2* and *MYC* translocations and/or *KMT2D* (*MLL2*) mutation. Gain/amplification of *MIR17HG* and its paralogue loci was observed in 50% of adult-mBL. In vitro studies suggested *miR-17~92*'s role in constitutive activation of BCR signaling and sensitivity to ibrutinib. Overall integrative analysis identified an interrelated gene network affected by copy number and mutation, leading to disruption of the p53 pathway and the BCR→PI3K or NF-κB activation, which can be further exploited in vivo by small-molecule inhibitors for effective therapy in adult-mBL. (*Blood*. 2017;130(16):1819-1831)

Medscape Continuing Medical Education online



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the American Society of Hematology. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Submitted 8 February 2017; accepted 22 July 2017. Prepublished online as *Blood* First Edition paper, 11 August 2017; DOI 10.1182/blood-2017-02-767335.

*A.B., C.B., and W.L. contributed equally to this study.

†W.C.C. and J.I. contributed equally to this study.

Presented in part at the 58th annual meeting of the American Society of Hematology, San Diego, CA, 5-8 December, 2016.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/blood>; and (4) view/print certificate. For CME questions, see page 1871.

Disclosures

Associate Editor Catherine M. Bollard served as an advisor or consultant for Collectis. CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC, owns stock, stock options, or bonds from Alnylam, Biogen, and Pfizer Inc. The authors declare no competing financial interests.

Learning objectives

Upon completion of this activity, participants will be able to:

1. Compare the copy number abnormalities (CNAs) and mutation profile of adult molecularly defined Burkitt lymphoma (mBL) vs pediatric mBL.
2. Distinguish recurrent mutations and CNAs in genes regulating phosphoinositide 3-kinase and B-cell receptor signaling in adult mBL.
3. Determine therapeutic and clinical implications of findings from this genomic analysis of adult mBL.

Release date: October 19, 2017; Expiration date: October 19, 2018

Introduction

Burkitt lymphoma (BL), the most common B-cell non-Hodgkin lymphoma (B-NHL) in childhood, accounts for 30% to 50% of NHLs in this age group. Although representing 1% to 5% of NHLs in adults,¹ the absolute number of adult-BL exceeds that of pediatric-BL.² The World Health Organization recognizes 3 variants: sporadic (sBL), endemic (eBL), and BL associated with HIV infection.³ Effective treatment of BL involves high-dose intensive chemotherapeutic regimens with a more than 80% probability of 5-year event-free survival in pediatric patients,⁴ but similar improvement in clinical outcome has not yet been achieved in patients with adult-BL, particularly in those older than 40 years.⁵

Gene expression profiling (GEP),^{6,7} immunoglobulin (Ig) mutation, and immunophenotypic analysis indicate a germinal center (GC) B-cell origin. The genetic hallmark is *MYC-IGH* translocation [t(8;14)(q24;q32)], which occurs in 80% of cases. *MYC-IGL* translocations [t(8;22) or t(2;8)] occur in 10% of BL.⁸ Approximately 10% of adult and 30% of pediatric cases of diffuse large B-cell lymphoma (DLBCL) also have *MYC* translocation, which may lead to misdiagnosis.⁹ This diagnostic distinction is critical because aggressive chemotherapeutic regimens are curative in BL, but standard regimens for DLBCL are inferior.

Genomic studies have uncovered novel disease-related abnormalities and refined pathogenic mechanisms that have assisted in more accurate BL diagnosis.^{6,7} However, most studies have focused on pediatric-BL,¹⁰⁻¹² with few comprehensive genomic studies in adult-BL. Array comparative genomic hybridization techniques revealed recurrent 1q21.1-q31.3 and 13q31 gains and 17p deletion in BL, but other aberrations were inconsistent.^{11,12} Therefore, we conducted an integrative analysis of the genomic copy number abnormalities (CNA), global GEP, and mutation analysis on adult cases (age >21 years) who were pathologically diagnosed as BL, Burkitt-like lymphoma, or DLBCL, but defined as BL by GEP, using a previously derived molecular signature.^{6,7} These cases were designated molecularly defined BL (mBL). We compared the CNA and mutation profile of these cases with pediatric-mBL and other

GC-derived B-NHL, including follicular lymphoma (FL), transformed FL (tFL), and de novo GCB-DLBCL. We identified recurrent mutations and CNA in genes regulating phosphoinositide 3-kinase (PI3K) and B-cell receptor (BCR) signaling in adult-mBL, which can be targeted by ibrutinib. This study illustrates that comprehensive genomic analysis can identify oncogenic pathways and reveal promising targets for novel therapeutic intervention in adult-mBL.

Methods

Detailed materials and methods are available in the supplemental Materials and methods, available on the *Blood* Web site.

Patient samples and B-cell lines

Select clinical characteristics are provided in Tables 1 and 2 and supplemental Table 1A. Genomic data from published series of mBL (12 adults, 18 pediatric), FL, tFL,¹³ and GCB-DLBCL^{14,15} were included for comparative analysis. The genetic characteristics of BL cell lines are tabulated in supplemental Table 1B, and cell culture details are in the supplemental Materials and methods.

Structural and functional genomic analysis

Comparative genomic hybridization and copy number analysis. CNA analysis was performed as previously described¹³ and is also detailed in the supplemental Materials and methods.¹⁰

Target gene section and whole-exome capture and data analysis. A panel (n = 380) targeting genes mutated (≥5%) in NHLs was designed. Libraries were prepared from genomic DNA, and exomes were captured with the Kapa Biosystems exome enrichment kit per manufacturer's protocol (Kapa Biosystems, Inc). Data analysis was performed as previously described¹⁶ and detailed in the supplemental Materials and methods.

Gene and miRNA expression analysis. The GEP data from a previous study⁶ were used to classify samples as BL or DLBCL, using a Bayesian classifier.⁶

Table 1. Clinical characteristics: molecular BL cases

			Path diagnosis			
			Adult		Pediatric	
			BL	DLBCL	BL	DLBCL
	Adult	Pediatric				
Current study						
Total	22	39	18	4	36	3
Male	14	32	12	2	30	2
Female	8	7	6	2	6	1
Average age (range)	56.6 (27-82)	9.2 (3-20)				
GSE21597						
Total	9	13				
Male	5	12				
Female	4	1				
Average age, y (range)	41 (24-63)	7.3 (2-13)				
Total	28	45				

Differential gene expression and association with CNA status (gain, loss, normal) were analyzed by Student *t* test, using approaches described in earlier studies.⁹ miRNA expression was generated previously,¹⁷ using the TaqMan human microRNA array.

MYC and BCL2 protein expression and translocation status

Tissue microarrays were stained with MYC and BCL2 antibodies, as described previously.^{18,19} More than 50% staining was the positive threshold. Supplemental Table 7 summarizes cases with MYC or the BCL2 translocation identified by sequencing, fluorescence in situ hybridization, and validation by long-range polymerase chain reaction.²⁰

Survival outcome analysis

Overall survival was estimated using the Kaplan-Meier method, and differences were assessed using the log-rank test.

Functional validation using in vitro assays in BL cell lines

Quantitation of MYC and miRNA17~92. Expression of *MYC* and *miR17~92* was estimated by quantitative reverse transcription polymerase chain reaction (primers in supplemental Table 8), and microRNA 17~92 (*miR17~92*) cluster members were evaluated by TaqMan small RNA assays.

MYC and miRNA17~92 knockout/knockdown in cell lines. *MYC* and *MIR17HG* knockout was performed using CRISPR-mediated gene editing (single-guide RNA sequences listed in supplemental Table 8). Functional loss of *miR17~92* was performed using a previously described miRNA sponge.²¹ Sponge efficiency was estimated by expression of miRNA17~92 targets (BIM and PTEN).

Evaluation of BCR signaling and in vitro ibrutinib treatment. BCR activation status was estimated by the phosphorylation status of upstream regulators (BLNK, BTK, and SYK) and a downstream effector (ERK) after IgM treatment and BCR inhibition was performed using ibrutinib, as detailed in the supplemental Data (supplemental Figure 11).

Cell proliferation. Cell proliferation was estimated using Presto Blue/CyQUANT (Thermo Fisher, Inc). Apoptosis rate was calculated using FACSCalibur (BD Biosciences) after Annexin-V staining (BioLegend, Inc). Cell cycle was analyzed with a BD LSR II flow cytometer after propidium iodide staining.

Results

Patient characteristics and molecular classification of BL by GEP

Clinical characteristics of the 61 mBL cases by GEP are summarized in Tables 1 and 2. Figure 1A-B depicts expression of the previously defined molecular BL signature⁶ and validation of the classification using a different molecular-BL classifier.⁷ Pediatric-mBL and

adult-mBL cases were indistinguishable by the classifier and distinct from cases diagnosed as BL by pathology, but molecularly classified as DLBCL or unclassifiable (non-mBL) and t(8;14)-positive DLBCL²² (Figure 1A). Examination of the molecular classifier in other BL series (GSE69053²³ and GSE4475⁷) confirmed that adult-mBL and pediatric-mBL showed concordant gene signatures (supplemental Figure 1A-D). Patients with adult-mBL, however, had significantly worse overall survival⁵ (Figure 1C), as also noted in a previous study²³ (supplemental Figure 1D). Adult and pediatric patients with mBL had a similar proportion of t(8;14)-positive cases and similar morphological features, but on genomic analysis, several genetic characteristics differed significantly (supplemental Figure 1E; supplemental Table 1A).

Structural genomic (CNA and mutation) analysis of mBL and other GC-derived B-NHLs

A total of 73 cases were included for CNA analysis (51+22 mBL cases from an earlier study¹⁰). The 2 cohorts showed similar genomic profiles (supplemental Figure 2A) and were combined to identify recurrent CNA. Comparison of the mBL cohort with other GC-derived B-NHL (ie, FL, tFL, and de novo GCB-DLBCL)^{13,14} showed that a smaller percentage of the mBL genome (5.7%) was aberrant compared with other GC-derived B-NHLs (FL, 11%; tFL, 17%; GCB-DLBCL, 17%; Figure 2A), consistent with cytogenetic studies.⁸ Most chromosomes showed some degree of aberration in mBL, with a few loci unique (del11q23.3-11q25) or more frequently (del13q14-21, del22q11) or more focally (13q31.3 gain) altered in mBL compared with FL, tFL, and GCB-DLBCL (Figure 2B-C; supplemental Figure 2B-C). Despite the low genomic complexity of the mBL genome, some aberrations were as frequent as 20% to 35% (1q12-21 gain, 13q31.3 gain, cnLOH-17q; Figure 2B-C; supplemental Figure 2B-C,E). Loss of genomic regions encompassing well-characterized tumor suppressors (TS) or cell cycle regulators, including *TP53* (17p13.1), *RBI* (13q14.2), and *CDKN2A/2B* (9p21.3), was common in mBL, although not as frequent as in other NHLs. However, del22q11, del11q23.3-11q25, and focal gain of 13q31.3 occurred more frequently in mBL than in other GC-derived B-NHLs.

Mutation data were generated for 52 mBLs (Figure 3A; supplemental Tables 2 and 3), and *MYC* (58%), *ID3* (46%), *TP53* (44%), *DDX3X* (31%), *CCND3* (29%), *SMARCA4* (25%), and *TCF3* (21%) were mutated frequently in mBL, more so than in other GC-derived B-NHLs²⁴ (supplemental Figure 2F), and similar to earlier BL studies²⁵⁻²⁷ (supplemental Figure 2G). Several mutated genes (*TCF3*, *CDH23*, *CSMD2*, *BCL7A*, and *EPPK1*) were unique to BL, and genes associated with the chromatin remodeling complex SWI/SNF (*SMARCA4*, *ARID1A*, and *ARID1B*) were frequently mutated in mBL.

Table 2. Clinical characteristics: nonmolecular BL cases (BL by pathology diagnosis), n = 17

			Path diagnosis					
			DLBCL subtype					
			Adult			Pediatric		
			ABC	GCB	UC	ABC	GCB	UC
Current study								
Total	7	10	5	1	1	1	7	2
Male	5	7	3			1	5	1
Female	2	3	2	1	1		2	1
Average age, y (range)	76.29 (62-85)	6.4 (2-11)						




Figure 1. Adult and pediatric-mBL cases are indistinguishable by the Burkitt classifier but have distinct CNAs. (A) Heat map showing expression of genes in the Dave et al⁶ and Hummel et al⁷ Burkitt classifiers for a BL and DLBCL training cohort and a validation cohort consisting of adult-BL, pediatric-BL, nonmolecularly classified Burkitt, and t(8;14)-positive DLBCL tumors. MYC and BCL2 translocation status of the 61 cases in the study are noted, and cases in which the translocation status comes solely from NGS data are marked (-). (B) Comparison of the mBL probability score predicted by the Dave et al⁶ and Hummel et al⁷ BL classifiers. Three cases classified as Burkitt by the Dave classifier would be classified as intermediate by the Hummel classifier. (C) Kaplan-Meier curves comparing overall survival of adult and pediatric molecularly classified Burkitt cases. The adult-BL series shows dismal clinical outcome, which may be attributed to suboptimal treatment, diagnostic challenges (before the GEP era), double-hit cases with mBL features, and advanced age (median, 55 years).

RYR1, *ARID1B*, *BCL7A*, and *PLCE1* mutations, present in 10% of mBL, have not been previously reported.²⁵⁻²⁷

MYC mutations were never observed in the DNA binding domain (supplemental Figure 3A), but were confined to the activation domain within the MYC box I and PEST domains and at a hotspot affecting a proline residue (*MYC*^{P72/S77}), whose mutation results in inhibition of ubiquitin-mediated degradation.²⁸ No association with *MYC* mRNA or CN status was observed with mutation status. *TP53* mutations occurred only in the DNA binding domain (supplemental Figure 3B) and included hotspot mutations affecting R248 (n = 4) and R273 (n = 2).²⁹ Several *TP53* mutations were accompanied by copy neutral loss of heterozygosity (cnLOH) or copy loss. Cases with copy loss or cnLOH have significantly lower expression of *TP53* than those without mutation or CNAs (~2-fold change *P* = .04; supplemental Figure 4A). *ID3* mutations occurred in the helix-loop-helix domain and were accompanied by LOH of *ID3* (supplemental Figure 3C; Figure 3A).²⁵⁻²⁷ Another *ID3* mutation affecting a splice-donor site, reported to result in deletion of amino acids 82-100,²⁷ occurred in several cases. *TCF3* mutations were located in the helix-loop-helix domain (supplemental Figure 3E) and likely interfere with regulation by *ID3*.²⁷ Correlation of GEP and mutation status (supplemental Figure 4B) indicated that cases with *ID3* mutation expressed higher levels of *ID3* mRNA, in agreement with a previous study.²⁵ Consistent with previous studies,^{26,27} most *CCND3* mutations affected the carboxy terminus with 2 hotspots (I290 and T271; supplemental Figure 3D). Several other genes showed

differential mRNA expression based on mutation status (supplemental Figure 4B).

Structural genomic (CNA and mutation) analysis in adult and pediatric-mBL

A higher proportion of the BL genome was aberrant in adult compared with pediatric cases (Figure 2A; supplemental Table 4). Figure 2C and supplemental Figure 2D illustrate that adult-mBLs have a higher frequency of abnormalities at any genomic locus except 22q11.22.

13q31.3 gain, affecting *MIR17HG*(*miR17~92* cluster) occurred more than twice as frequently in adult as in pediatric cases (36% vs 16%; Figure 4A; Fisher's exact test *P* = .08), and was associated with increased expression of *miR17~92* members, as measured by quantitative reverse transcription polymerase chain reaction (Figure 4B). The frequent *MIR17HG* gain in adult BL was validated in a separate BL cohort (n = 27) profiled using whole exome sequencing (WES)²⁵ (Figure 4C). *miR17~92* paralogues (*miR106b~25* at 7q22.1, and *miR106a~363* at Xp26.2), which share the same seed sequence, were affected by copy gains, with *miR106a~363* more frequent in adult-mBLs (Figure 4A). Gain/amplification of *miR17~92* or paralogues occurred in 50% (14/28) of adult-BL compared with 27% (12/45) of pediatric-BL (Figure 4D; Fisher's exact test *P* = .05). Although miRNA expression was not increased in cases with gain of the paralogues, expression of *miR17~92* and its paralogues was higher in mBL than in DLBCL




Figure 2. CNAs in germinal center B-cell-derived lymphomas. (A) Box plot of the proportion of the aberrant genome (change in genome content) for the noted GC-B-cell-derived NHL entities. (B) Bar graph of the frequency or recurrent CNAs in different lymphomas. CNAs with significantly different ($P < .05$) frequency of CNAs are denoted (*). (C) Circos plots comparing the frequency of gains and losses found in the noted lymphoma types. Darker shades denote regions of amplifications or homozygous copy loss and axis lines represent 20%.

(supplemental Figure 5A-B). Adult-mBL patients with *MIR17HG* gain had worse overall survival (Figure 4E), and gene set enrichment analysis identified enrichment of gene signatures associated with immune suppression or hypoxia (eg, transforming growth factor β and hypoxia inducible factor 1- α target signature) and chemotherapy resistance in adult cases with *MIR17HG* gain (supplemental Figure 5C). In contrast, MYC and E2F target signatures and proliferation signatures were enriched in *MIR17HG* WT cases (supplemental Figure 5C).

8q22-q24 gain was only observed in adult-mBL (30%) (Figure 4F). Several genes showed increased expression with CN gain, including *MTBP*, a likely MYC transcriptional target, MYC-interacting protein, and regulator of proliferation³⁰ (Figure 4G), and *UBR5*, an E3 ubiquitin ligase mutated in 2 adult-mBL cases and known to be affected by CNA/mutation in tumors.²⁷ Unexpectedly, cases with MYC gain (8q) had low MYC mRNA expression compared with wild-type cases

(>2-fold change, $P < .001$; Figure 4H) and low protein expression by immunohistochemistry (0/4 MYC positive in 8q24 gain vs 6/10 MYC positive in 8q24-WT; $P = .085$; Figure 4I). MYC mRNA expression was higher in pediatric compared with adult-mBL (mRNA, $P = .014$; Figure 4H), more pediatric cases were positive for MYC protein expression (7/10 in pediatric vs 6/15 in adult), and enrichment of MYC target gene expression was observed in pediatric-mBL compared with adult-mBL (Figure 4J).

18q gain was more frequent in adult-mBL than pediatric-mBL (Figure 2C; supplemental Figure 2D; 18% vs 9%), and genes on 18q with a concomitant increase in mRNA expression with CNA included *BCL2*, *MALT1*, *TCF4*, *SOCS6*, and *PIAS2* (supplemental Figure 6F). *BCL2* mRNA was ~4 fold higher in cases with 18q gain, and *BCL2* gain/translocation was associated with *BCL2* protein expression (supplemental Figures 5A-B and 6F). Another *BCL2* family member, *MCL1* at chr1q21 crucial for MYC-driven lymphoma maintenance,³¹




Figure 3. Select CNA or genes found to be recurrently mutated in 52 mBL cases. (A) The block color represents the type of mutation. Blocks with 2 colors indicate that more than 1 type of mutation was observed. Genes also affected by copy number abnormalities are noted (G, copy gain; L, copy loss; N, copy neutral loss of heterozygosity). *MYC* and *BCL2* translocation status is shown and *MYC*, *BCL2*, and *Ki67* mRNA expression relative to the median is depicted. (B) Copy number and/or mutation status of *RB1*, *CDKN2A/CDKN2B*, and *CCND3* for individual mBL tumors.

showed similar frequency of CN gain in adult and pediatric-mBL (~35%), and did co-occur with *BCL2* aberrations. *BCL2* and *MCL1* coexpression occurred in BL cell lines (supplemental Figure 10C), and

they were more sensitive to the pan-*BCL2/MCL1/BCL-XL/BCL2A1* inhibitor Sabutoclax than to selective *BCL2* (ABT-199) or *MCL1* (A1210477) inhibitors (Figure 5C).




Figure 4. *MIR17HG* and Chr8q are gained in mBL. (A) Frequency of DNA CN gains found in adult (red-orange) or pediatric (blue) mBL for *MIR17HG* and paralogues *MIR106B* and *MIR106A*. (B) Heat maps of expression of the *MIR17*~92 cluster members measured by TaqMan Array Human MicroRNA A Card (ABI) in tumors with and without *MIR17HG* DNA copy number gain. (C) Validation of the frequency of *MIR17HG* DNA CN gain in adult-BL using a published BL genomic/WES dataset. CN status was assessed using Varscan2 CNV followed by segmentation by the Circular binary segmentation algorithm. For WES data, regions of gain were cut off at a threshold of 0.2 log₂ ratio. (D) Copy number status of *MIR17HG* and paralogues for individual tumors (gain = red, loss = green). (E) Kaplan-Meier curves comparing overall survival adult-mBL cases by *MIR17HG* copy number status. Several *MIR17HG* gain/amplified cases also had double *MYC*/ *BCL2* translocation/mutation, but showed BL mutation and GEP profile. (F) Plot of CNAs along chromosome 8 for mBL cases with abnormalities. (G) Bar graph of the fold increase in expression of genes along chromosome 8 that are significantly upregulated ($P < .05$, 1-sided Student t test) in cases with CN gain. Genes of interest are noted. (H) Boxplot of *MYC* mRNA expression by *MYC* DNA copy number status and by age. Red points represent expression values of individual cases. Expression levels in normal centroblasts (CB), CD77-negative cells, and naive B cells (NBC) are noted for comparison. (I) *MYC* protein expression in 3 cases with *MYC* gain and 3 cases with a *MYC* DNA copy number=2. (J) Signatures upregulated on *MYC* overexpression were enriched in pediatric-mBLs compared with adult-mBLs.




Figure 5. 18q21 gain or BCL2 translocation is associated with BCL2 protein expression. (A) BCL2 IHC was performed and scored on adult-mBL cases with no evidence of *BCL2* gain/translocation based on clinical data, NGS, and SNP array ($n = 7$) and cases with *BCL2* gain/translocation ($n = 6$). Bars represent the mean expression score and error bars represent 1 standard deviation. (B) Example of BCL2-positive and BCL2-negative staining cases (original magnification, $\times 20$). (C) BL cell lines are sensitive to a pan-BCL2 inhibitor compared with single-agent inhibitors. Bars represent the mean of 3 replicates from 1 representative experiment of at least 3 separate experiments, and error bars represent 1 standard deviation.

Loss of genomic loci (6q21-25, 9p21.3, 13q14-q21.2, and 17p13.1) encompassing well-characterized TS genes was frequent ($\sim 10\%$ – 20%) in adult-mBL. *Del17p13.1* affecting *TP53* was twice as frequent in adult-mBLs as in pediatric-mBLs (18% vs 9%); however, *TP53* cnLOH and/or mutation occurred at equal frequency (11% cnLOH and $\sim 45\%$ mutation). Focal *del9p21.3* encompassing *CDKN2A/CDKN2B* (14% adult, 9% pediatric) and *del13q14.2* affecting *RBI* (18% adult and 7% pediatric) were found. *RBI* mutations were only identified in adult-mBL ($\sim 15\%$, 3/21), and cases with *RBI* copy loss and/or mutation had an average 3-fold or higher decrease in mRNA expression compared with WT cases. Although *CDKN2A/CDKN2B* loss and *RBI* copy loss/mutation did not co-occur, the sample number was insufficient to determine the significance of mutual exclusivity (Figure 3B).

1q21-q25.3 gain/amplification, proximal to the centromere, was present with similar frequency ($\sim 35\%$ to 40%) in adult and pediatric-mBL, but the frequency of the distal loci (1q25.3-1q42.13 gain) was higher in adults (30% to 40% vs 10% to 25%, Figure 2C; supplemental Figure 2D), and included genes whose encoded proteins negatively regulate p53 stability (*MDM4*), ubiquitinate MYC (*FBXO28*), or are primarily associated with proliferation/survival (*RGS16*, *BTG2*, *EIF2D*, *CENPF*, *ASPM*) and gene expression levels correlated with CN status ($P < .05$ and > 1.5 -fold change; supplemental Figure 6A). In addition, 1q25 gain encompassing *MDM4* (36% adult, 18% pediatric) and 12q15 gain containing *MDM2* (14% adult, 4% pediatric), were also noted in mBL; gene expression showed that CN gain led to higher mRNA expression (> 2 -fold, $P < .01$). Additional genes within recurrently aberrant loci had associated gene expression changes and may contribute to lymphomagenesis (supplemental Figure 6A-F).

Del22q11 was seen primarily in pediatric-mBL (33% vs 10%; Figure 2C; supplemental Figure 2D; supplemental Table 4; CNA #128) and may relate to *IGL* rearrangement.³² Two genes (*ZNF280B* and *VPREB1*) within the deleted had corresponding low mRNA expression with CN loss.

Mutational landscape in adult-mBL and pediatric-mBL

The frequencies of commonly mutated genes (eg, *MYC*, *ID3*, *TP53*, *CCND3*, *DDX3X*, *ARID1A*, and *TCF3*) were not significantly different in adult-mBL and pediatric-mBL (Figure 3A; supplemental Tables 2 and 3). However, *BCL2* (43% vs 0; $P < .001$), *ZFH3* (24%; $P < .01$), *SPTBN5* (20%; $P = .02$), *RBI* (14%; $P = .06$), *BTG1* (14%; $P = .06$), *TCF4* (14%; $P = .06$), and *TNFRSF14* (14%; $P = .06$) were exclusively mutated in adult-mBL. In contrast, mutations in *CDH23* (29% vs 5%; $P = .04$), *SMARCA4* (35% vs 19%; $P = .05$), *RYR3* (13% vs 0; $P = .14$), and *RYR1* (29% vs 10%; $P = .16$) were more frequent in pediatric-mBL. Of note, *SMARCA4* (25% all mBL) and *KMT2D* (15% all mBLs) mutations were mutually exclusive ($P = .04$, CoMet³³). Two Gα subunits of G-protein-coupled receptors, *GNA13* and *GNAI2*, were mutated more frequently in pediatric-mBL (29% vs 9.5% and 16% vs 9.5%, respectively), and mutation only co-occurred in 1 sample (Figure 3A).

Analysis of coding and noncoding mutations in genes known to be targeted by activation induced cytidine deaminase³⁴ showed more mutations/case in adult-mBLs compared with pediatric-mBLs (29 vs 15). Cases with known *MYC* or *BCL2* translocations had more noncoding *MYC* and *BCL2* mutation, respectively (supplemental Figure 7A). Cases with 10 or more mutations in *MYC* were frequent in pediatric-mBL (77% vs 33%). In contrast, more than 10 mutations in

BCL2 or *BCL6* occurred more frequently in adult-mBL (*BCL2*: 33% vs 0%; *BCL6*: 24% vs 3%; supplemental Figure 7B). No coding mutation was observed in *BCL6* in adult-BL.

Mutations and CNA define major oncogenic pathways in adult-mBL

Mutations in genes regulating the PI3K-AKT pathway (*TCF3*, *ID3*, *PTEN*, and *PLCE1*) did not show a significant difference between adult and pediatric cases. However, mutations in BCR signaling effectors that induce chronic active NF- κ B signaling (*CD79A*, *SYK*, *MYD88*, *BCL10*, and *CARD11*) were more frequent in adult-mBL (any mutation: 19% vs 7%). Several genes involved in NF- κ B pathway activation, including *MALT1* at 18q, *BCL11A* and *REL* at 2p16, and *TRAF5* and *TRAF3IP3*s at 1q32, were aberrantly gained in adult-mBL, with concomitant up-regulated mRNA expression.

Genes associated with mature B-cell development/differentiation (*IRF8* and *PAX5*) were mutated only in adult-BL (either mutation: 19% vs 0), in contrast to genes associated with GC differentiation (*BCL6* [coding], *NOTCH1*, *NOTCH2*), which were found in pediatric-mBL (16% of pediatric cases with any mutation vs none). Mutations that regulate the S1P/S1PR pathway (*GNAI3*, *GNAI2*) were primarily observed in pediatric-BL (Figure 3A). Many *GNAI2* mutations were missense mutations; a recent study suggested that mutations in *GNAI2* may be gain-of-function.³⁵ *GNAI3* couples to S1PR2 and results in inhibition of PI3K/AKT signaling, whereas *GNAI2* couples to S1PR1 and promotes PI3K/AKT signaling.

We observed differences in gene signatures and signaling pathways between adult and pediatric-mBL (supplemental Figure 8A).³⁶ Further analysis using gene set enrichment analysis³⁷ identified enrichment of STAT3 targets and ubiquitin-mediated proteolysis signatures in adults, whereas the S1PR pathway and genes induced on MYC overexpression were enriched in pediatric-mBL (supplemental Figure 8B). Many enriched gene signatures or pathways in adults are likely a result of differences in the frequency of *MIR17HG* gain, or mutations unique in these 2 age groups. For example, JAK-STAT pathway mutations occurred only in adults, whereas *GNAI3* and *GNAI2* mutations were primarily in pediatric-mBL. Enrichment of MYC-regulated genes may be a result of MYC expression differences between the 2 groups (Figure 4H,J). Differentially expressed genes in adult-mBL (vs pediatric-BL) showed similarity to adult NHL, as well as BL cell lines, even though the majority of these cell lines are derived from pediatric patients (supplemental Figure 8A).

Integrative analysis of genomic abnormalities with gene expression

Genes with significant expression changes with CNA status (reduced expression with loss or increased expression with gain) were compiled, and DAVID (<https://david.ncifcrf.gov/>) showed enrichment of genes involved in cell cycle, the ubiquitin pathway, and TP53 signaling (supplemental Table 5).

Hierarchical clustering of recurrent CNAs and mutations (present in $\geq 10\%$ of mBL) showed that cases clustered into 2 main groups, dominated by the 2 age subgroups (supplemental Figure 9A). Abnormalities more frequent in the adult cases formed 1 cluster, whereas genetic events frequent in pediatric cases (*SMARCA4*, *GNAI3*, *DDX3X*, and *OBSCN*) formed another cluster with only few cases interspersed, suggesting distinct oncogenic mechanisms in the age-defined subgroups.

We analyzed the co-occurrence of the most frequent genetic alterations, using Pearson correlation, and observed a negative correlation of *MIR17HG* copy gain with chromosome 17p-cnLOH

and *SMARCA4* mutation (supplemental Figure 9B). *TP53* mutation and del17p13.2 were positively correlated (supplemental Figure 9B). *TP53* mutations were detected in all cases with copy loss or cnLOH, but several mBL cases only had *TP53* mutation (Figure 3A).

Functional losses of MYC and miRNA17~92 inhibit proliferation

MIR17HG gain, despite being a bona fide MYC target, showed negative correlation ($r = -0.23$) with MYC expression in tumors (noted in an earlier study¹²; Figure 6A), although a feedback loop fine-tuning MYC expression by miR17~92 has recently been demonstrated in vitro.³⁸ Significantly higher miRNA expression of *miR17~92* cluster members in BL than in DLBCL (supplemental Figure 5B) or normal GC-B cells¹⁷ suggested a distinct role of *miR17~92* in BL pathogenesis. To validate this observation further through in vitro analysis, we examined *MIR17HG/miR17~92* and MYC status (CN, mRNA) in 6 BL cell lines, including 1 from an adult (GA-10).³⁹ Three cell lines (Namalwa, Daudi, Ramos) had *MIR17HG* gain/amplification and 3 (Namalwa, Raji, P3HR1) had MYC gain/amplification. Despite having normal MYC and *MIR17HG* CN status, GA-10 showed high mRNA expression of MYC and miR17~92 cluster members (miR-17, miR-19b, and miR-92a), comparable to those with CN gain (supplemental Figure 10A). Unlike primary tumors, MYC CN status and mRNA expression were positively correlated in cell lines (supplemental Figure 10B). BIM, a miR17~92 target, had lower expression in cell lines with *MIR17HG* gain (supplemental Figure 10C).

We tested whether the absence of MYC (CRISPR-mediated knockout [KO] of MYC) and/or functional loss of *miR17~92* using sponge affected the proliferation and survival of BL cell lines. Sponge effectiveness was assessed using known target genes (*PTEN* and *BIM*), and increased expression (>1.25 - to 2.5 -fold) of target genes was observed, excluding P3HR-1, which does not express *PTEN* (Figure 6B-C). Consistent with a role in fine-tuning MYC expression,³⁸ a moderate increase in MYC expression was noted in at least 2 cell lines (Figure 6B-C). MiR17~92-sponge expression led to significantly reduced proliferation (Figure 6D) and G₁-S cell cycle arrest in 3 of 4 tested BL cell lines (supplemental Figure 10D). Similar results were obtained with the GA-10 cell line and the Daudi cell line with copy loss of *MIR17HG* by CRISPR/Cas9 (Figure 6D; supplemental Figure 10E-H). When stressed with reduced serum, miR17~92 sponge-expressing cells had reduced proliferation (supplemental Figure 10I). Although there was a proliferative disadvantage on miR17~92 inhibition, only Daudi cells showed an increase in apoptosis (supplemental Figure 10J), possibly as a result of high expression of antiapoptotic proteins (*BCL_{XL}* and *MCL1*; supplemental Figure 10C). MYC KO decreased cell proliferation (Figure 6F; supplemental Figure 10K) and increased sensitivity to serum deprivation (supplemental Figure 10L), but miR17~92 sponge-expressing MYC KO cells showed no major difference in proliferation/viability.

MIR17~92 expression induces BCR signaling in BL cell lines and can be targeted by ibrutinib

MIR17~92 inhibits negative regulators of BCR signaling by directly targeting immune-receptor tyrosine-based inhibitory motif-containing genes *CD22* and *FCGR2B* (Figure 6E).⁴⁰ IgM crosslinking in BL cell lines induced BCR signaling, as measured by kinase activity (phosphorylation) of immediate upstream tyrosine kinase (*p*-SYK), adaptor protein (*p*-BLNK), effector protein (*p*-BTK), and downstream regulators (*p*-ERK).⁴¹ We observed consistently reduced phosphorylation of the above-mentioned BCR regulators in the miR17~92 sponge-expressing BL cell lines, including GA-10 and the genetically




Figure 6. Evaluation of functional significance of MYC and MIR17HG in BL tumors and cell lines. (A) Comparison of average *miR-17-92* expression and MYC expression in mBL tumors. *miR17-92* expression levels were inversely correlated with MYC expression in tumors ($r = -0.23$). (B) Whole-cell lysates were western blotted for PTEN, Bim, MYC, and β -actin expression in the noted BL cell lines expressing empty vector (C) or a vector containing *miR17-92* sponge (S). (C) Bim, PTEN, and MYC expression was normalized to β -actin, and relative expression (sponge/vector control) was quantified from 2 separate western blot experiments. Error bars represent 1 standard deviation. (D) Proliferation in BL cell lines after *miR17-92* sponge expression or *MIR17HG* knock out (Daudi-CRISPR) and/or ibritinib (IBT) treatment. Line graph depicts 1 representative experiment of triplicate experiments, and points are the average of 3 biological replicates. Error bars represent 1 standard deviation. BL cell lines were treated with a specific concentration of IBT based on the 50% infective dose calculation for each line. (E) Comparison of mRNA levels of *CD22* and *FCGR2B* in control (vector or parental) or *miR17-92* sponge or knockout (Daudi-CRISPR) cells with or without IgM stimulation. Fold change was calculated relative to the vector or parental controls. Graph depicts 1 representative experiment of 3 separate experiments. Error bars depict 1 standard deviation of 3 technical replicates. (F) Cell proliferation in BL cell lines after MYC KO and/or *miR17-92* knockdown (sponge). Points represent the mean of 3 biological replicates from 1 representative experiment of at least 3 separate experiments. Error bars represent the standard error of the mean. (G) Western blots of whole-cell lysates from control (GFP or parental) or *miR17-92* sponge-expressing or *MIR17HG* knock-out (Daudi-Cas-9) BL cell lines after induction of BCR signaling with anti-IgM. (H) Relative expression of phosphorylated/total SYK, BTK, BLNK, and ERK was quantified from the western blot, suggesting decreased BCR signaling in *miR17-92* sponge-expressing or KO BL cell lines.

edited Daudi cell line (*MIR17HG* KO) (Figure 6G-H), suggesting a positive regulation of BCR activation by *miR17-92*. The above observation was corroborated by increased mRNA expression of either 1 or both *miR17-92* targets (*CD22*, *FCGR2B*) in sponge-expressing

BL cell lines (Raji and Daudi). The increase in expression in sponge-expressing cell lines increased significantly on IgM stimulation in 4 BL cell lines (Figure 6E). P3HR1 did not show consistent results. Similar results were observed with 2 other immune-receptor

tyrosine-based inhibitory motif-containing negative regulators of BCR signaling, which are direct (FCLRL4) or indirect (CD72) targets⁴⁰ of *miR17~92* (supplemental Figure 10M-N).

FCGR2B recruits SHIP, a phosphoinositol phosphatase, which leads to BTK and PLC γ dissociation and dampens BCR signaling.⁴² Therefore, we examined the sensitivity of BL cell lines to the BTK inhibitor ibrutinib at their IC₅₀ concentration with and without functional loss of *miR17~92*. The BL cell lines were sensitive to ibrutinib in a dose- and time-dependent manner, suggesting dependence on BCR signaling (supplemental Figure 11A-B). However, there was an additive effect of ibrutinib treatment in BL cell lines with *miR17~92* sponge vector compared with control cells, and this was also noted in the P3HR1 cell line. In BL cell lines expressing *miR17~92* sponge, ibrutinib treatment resulted in growth inhibition (Figure 6D). Interestingly, Nalwama cells, which had the highest level of *miR17~92* amplification, were the most sensitive to ibrutinib treatment (supplemental Figure 11B) and were further sensitized in the presence of the *miR17~92* sponge.

Discussion

Reexamination of mBL cases in view of the 2016 World Health Organization classification⁴³ indicated that 8 of 24 adult-mBLs may fit the high-grade B-cell lymphoma category. However, 7 cases had genetic characteristics similar to BL, including *MYC*, *ID3*, and *TCF3* mutation; del11q, del22q11, low *miR-155* expression (C_T value ≥ 30)¹⁷; and/or *CCND3* and *TP53* mutations, which are more frequent in BL than other NHLs. These cases had a lower frequency of FL/tFL-characteristic mutations (*EZH2*, *CREBBP*), but showed a *KMT2D* (*MLL2*) mutation frequency similar to FL (supplemental Figure 1E). These observations suggest that high-grade B-cell lymphomas with BL signature are not derived from FL or GCB-DLBCL, but may have arisen from a precursor that has acquired *BCL2* and *MYC* translocations and, in many cases, *KMT2D* mutation. The current adult mBL series has dismal outcome, similar to an earlier study (supplemental Figure 1D; data from Sha et al²³), but different from the adult BL series presented in Dunleavy et al treated with DA-EPOCH-R.⁴⁴ Suboptimal treatment, patient age (median age 25 years vs 55 years in this series), and diagnostic challenges may contribute to the poor outcome, but a recent meta-analysis of BL across the United States has shown inferior outcome in those older than 40 years, despite improvement in clinical outcome of younger patients.⁵

The current study showed that BL had fewer CN genomic changes than other GC-derived B-NHLs, indicating that *MYC* overexpression resulting from t(8;14) is a major driver of lymphomagenesis. This is not surprising, considering that *MYC* is an amplifier of global transcription,⁴⁵ regulating 10% to 15% of the transcriptome, especially genes regulating the cell cycle, growth, metabolism, and apoptosis.⁴⁶ Normally, *MYC* overexpression induces p53-mediated apoptosis, and tumors overexpressing *MYC* circumvent this by disrupting the p53 pathway.⁴⁷ Recurrent CNAs/mutations were identified in genes associated with p53 signaling, cell cycle regulation, or apoptosis, as shown in the results section (supplemental Table 6). Loss of p53 function by CN loss/mutation occurs in half of adult-mBL. *TP53* copy loss and cnLOH cases also had *TP53* mutation, but not vice versa, indicating mutation may occur earlier than CNA. Other regulators of p53 signaling pathway not previously reported include *TS* *EI24* and *TBRG1*, which are located within del11q21, a loss unique to mBL. These genes are involved in p53-mediated apoptosis⁴⁸ and impairment of MDM2-mediated inhibition of p53 transcriptional activity,⁴⁹ respectively.

Adult-mBLs had more CNAs than pediatric-mBLs, but fewer than other B-cell NHLs. Interestingly, del22q11 is unique to pediatric-BL,

and was not found in other adult-mBL cases except 3 double hit cases. Although the loss can be associated with *IGL* λ locus rearrangement,³² a similar rearrangement in CLL leads to *miR-650* upregulation.⁵⁰ Two other genes in this locus, *ZNF280B* (33% of pediatric mBL), which positively regulates MDM2 expression,⁵¹ and *VPREB1* (11% of pediatric mBLs), deleted in pediatric-ALL independent of *IGL* λ rearrangement,⁵² are downregulated in cases with copy loss, but their role in BL pathogenesis needs further investigation. Several genetic alterations were either unique (18q21 and 8q24 gain) or more frequent in adult BL (13q31 gain, del13q14, del6q21). Gain of 18q21 encompassed *MALT1*, *BCL2*, and *TCF4* and had corresponding upregulated mRNA and/or mutation. *BCL2* protein/mRNA expression was higher in adult BL, consistent with earlier studies,⁵³ and co-occurred with *MCL1* (1q21 gain) another antiapoptotic protein. BL cell lines were more sensitive to a pan-BCL2 inhibitor (Sabutoclax) than to agents targeting single BCL2 family members, suggesting a potential target in adult BL.

mBL had distinct mutations compared with other GC-derived B-NHL, with mutations in genes regulating the cell cycle (*MYC*, *CCND3*, *TP53*; all $P \leq .01$ for mBL vs GC-derived B-NHL), the BCR-PI3K pathway (*TCF3*, *ID3*), and chromatin modification (*SMARCA4*) associated with mBL. *TCF3* activates PI3K via BCR signaling,²⁷ but also promotes cell proliferation via direct activation of *CCND3*, essential for expansion of GC B-cells.⁵⁴ *ID3* and *TCF3* mutations impair the negative feedback between *TCF3* and *ID3*.²⁷ *CCND3* mutations, restricted to the C terminus, a domain crucial for the formation of activating complex with cyclin-dependent kinases (CDK4/CDK6), thus may inhibit interaction with the negative cell cycle regulators p21 and p27.⁵⁵ *CCND3* can inactivate RB1 by phosphorylation, and *RB1* deletion/mutations and *CCND3* mutations tend not to co-occur, suggesting they regulate a common pathway leading to proliferation.

SMARCA4, an epigenetic regulator, was primarily mutated in pediatric-mBL, whereas *KMT2D* (*MLL2*) mutations were mainly in adult-mBL. *SMARCA4* loss in B cells can lead to *IGH-MYC* translocations resulting from impairment of TOP1 recruitment to chromatin,⁵⁶ and may be a primary lesion in pediatric-BL. Genes that regulate JAK-STAT or chronic BCR-NF- κ B signaling and the SIP-pathway were more frequent in adult-mBL and pediatric-mBL respectively. The SIP pathway is frequently disrupted in GC-derived B-NHL, and its disruption impairs the confinement of B cells to the germinal center. Several genes were mutated only in adult-mBL, including the *TCF3*-related transcription factor *TCF4*, which was also associated with CN gain and elevated mRNA. *TCF4* mutation did not co-occur with *TCF3* mutation. Although they share homology and DNA-binding specificity, whether *TCF4* and *TCF3* functions are redundant needs further investigation.

MYC expression may be regulated by *miR17~92*, as it fine tunes *MYC* translation via Chek2-HuR,³⁸ an observation, noted in at least 2 BL cell lines (supplemental Figure 6C), in which sponge transduction led to a marginal increase in *MYC* protein expression. Consistent with this model, an inverse correlation between *MYC* and *miR17~92* expression was observed in BL cases. Furthermore, adult-mBL without *MIR17HG* gain had higher *MYC* expression and enrichment of a *MYC* gene target signature. Together this suggests an oncomiR may substitute for an oncogene in some adult-mBLs.²¹ *miR17~92* can modulate the function of multiple pathways promoting proliferation, chemoresistance,²¹ and BCR signaling⁴⁰ in B cells. The functional loss of *miR17~92* resulted in reduced proliferation in BL cell lines, which was further enhanced in stress conditions resulting from serum starvation, suggesting *miR17~92* expression is crucial for tumor survival. Loss of *miR17~92* in a cell line lacking expression of PTEN (P3HR1) did not have a significant effect on proliferation unless stressed with reduced serum, suggesting *miR17~92* acts partially through the PI3K pathway. The loss of functional *miR17~92* led to diminished BCR

signaling in BL cell lines, consistent with earlier findings in DLBCL cell lines,⁴⁰ thus demonstrating a positive role in B-cell activation. Because known targets of *miR17~92* include immune-receptor tyrosine-based inhibitory motif-containing genes (CD22, CD72, FCLR4, and FCGR2B), and FCGR2B also modulates BTK function via SHIP and PLC γ ,⁴² we tested the BTK inhibitor approved by the US Food and Drug Administration, ibrutinib, to inhibit BCR signaling in BL lines. Ibrutinib inhibited growth in all BL cell lines in a time- and dose-dependent manner with a range similar to an activated B-cell-DLBCL cell line. The additive growth inhibition of sponge-transduced BL cell lines on ibrutinib treatment suggests dual inhibition of BCR signaling and *miR17~92* by anti-miRs may prove therapeutically synergistic. Our earlier study has shown that BL and HG-BCL cases express elevated levels of *miR17~92* compared with other B-cell lymphomas.¹⁷ Now we have shown that *MIR17HG* focal amplification leads to even higher *miR17~92* expression levels, and thus these patients in particular may benefit from the above therapeutic approaches. However, further evaluation of these inhibitors in vivo is necessary for clinical application, and a more specific BTK inhibitor, such as acalabrutinib, may prove beneficial in adult-BL because of its low toxicity and the ability to transit the blood-brain barrier to reduce central nervous system involvement in BL.

Acknowledgments

The authors would like to acknowledge the Flow Cytometry Research Facility and the Tissue science facility for immunohistochemistry

staining at University of Nebraska Medical Center. J.I. was supported in part by the Lymphoma Research Foundation (F-263549), translational research program of Leukemia and Lymphoma Society (6129-14), and National Institutes of Health, National Cancer Institute Eppley Cancer Center Support Grant (P30CA036727). W.C.C. is supported by City of Hope Cancer Center Support Grant (P30CA33572) and Lymphoma SPORE developmental project grant (1 P50 CA 136411-01 01A1 PP-4).

Authorship

Contribution: A.B., C.B., W.L., W.C.C., and J.I. designed and performed the study; W.Z., A.K., T.H., C.M.L., J.Y., R.F., N.E., A. Reddy, T.W.M., and M.G. assisted in research, data analysis, and interpretation; T.C.G., J.V., D.D.W., R.D.G., A. Rosenwald, G.O., E.C., L.M.R., E.S.J., R.M.B., R.S., R.R.M., S.D., J.D., L.M.S., J.Y.S., K.F., and W.C.C. provided materials, reviewed pathology results, or contributed clinical/array comparative genomic hybridization/GEP data; and A.B. and J.I. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Javeed Iqbal, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-7660; e-mail: jiqbal@unmc.edu; and Wing C. Chan, Department of Pathology, City of Hope Medical Center, Duarte CA, 91010; e-mail: jochan@coh.org.

References

- Burkhardt B, Zimmermann M, Oschlies I, et al; BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. *Br J Haematol*. 2005;131(1):39-49.
- Perkins AS, Friedberg JW. Burkitt lymphoma in adults. *Hematology Am Soc Hematol Educ Program*. 2008;2008:341-348.
- Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. *Blood*. 2014;124(19):2913-2920.
- Hoelzer D, Walewski J, Döhner H, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. *Blood*. 2014;124(26):3870-3879.
- Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. *Blood*. 2013;121(24):4861-4866.
- Dave SS, Fu K, Wright GW, et al; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med*. 2006;354(23):2431-2442.
- Hummel M, Bentink S, Berger H, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biological definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med*. 2006;354(23):2419-2430.
- Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. *Leukemia*. 2009;23(2):225-234.
- Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. *Blood*. 2012;119(21):4939-4948.
- Scholtysik R, Kreuz M, Klapper W, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of Deutsche Krebshilfe. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. *Haematologica*. 2010;95(12):2047-2055.
- Salaverria I, Zettl A, Beà S, et al; Leukemia and Lymphoma Molecular Profiling Project (LLMPP). Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. *Haematologica*. 2008;93(9):1327-1334.
- Schiffman JD, Lorimer PD, Rodic V, et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. *Br J Haematol*. 2011;155(4):477-486.
- Bouska A, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. *Blood*. 2014;123(11):1681-1690.
- Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci USA*. 2008;105(36):13520-13525.
- Scandurra M, Mian M, Greiner TC, et al. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. *Br J Haematol*. 2010;151(3):221-231.
- Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. *Proc Natl Acad Sci USA*. 2015;112(10):E1116-E1125.
- Iqbal J, Shen Y, Huang X, et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. *Blood*. 2015;125(7):1137-1145.
- Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. *Clin Cancer Res*. 2011;17(24):7785-7795.
- Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *J Clin Oncol*. 2012;30(28):3452-3459.
- Basso K, Frascella E, Zanesco L, Rosolen A. Improved long-distance polymerase chain reaction for the detection of t(8;14)(q24;q32) in Burkitt's lymphomas. *Am J Pathol*. 1999;155(5):1479-1485.
- Rao E, Jiang C, Ji M, et al. The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. *Leukemia*. 2012;26(5):1064-1072.
- Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. *N Engl J Med*. 2008;359(22):2313-2323.
- Sha C, Barrans S, Care MA, et al. Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. *Genome Med*. 2015;7(1):64.
- Bouska A, Zhang W, Gong Q, et al. Bouska A, Zhang W, Gong Q, et al. Combined copy number

- and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. *Leukemia*. 2017;31(1):83-91.
25. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. *Nat Genet*. 2012;44(12):1321-1325.
 26. Richter J, Schlesner M, Hoffmann S, et al; ICGC MMML-Seq Project. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet*. 2012;44(12):1316-1320.
 27. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*. 2012;490(7418):116-120.
 28. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. *Blood*. 2000;95(6):2104-2110.
 29. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. *Genes Dev*. 2012;26(12):1268-1286.
 30. Grieb BC, Gramling MW, Arrate MP, et al. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. *Cancer Res*. 2014;74(13):3591-3602.
 31. Kelly GL, Grabow S, Glaser SP, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. *Genes Dev*. 2014;28(1):58-70.
 32. Mraz M, Stano Kozubik K, Plevova K, et al. The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. *Leuk Res*. 2013;37(7):802-808.
 33. Leiserson MD, Wu HT, Vandin F, Raphael BJ. CoMET: a statistical approach to identify combinations of mutually exclusive alterations in cancer. *Genome Biol*. 2015;16:160.
 34. Qian J, Wang Q, Dose M, et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. *Cell*. 2014;159(7):1524-1537.
 35. Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. *Blood*. 2013;122(7):1256-1265.
 36. Deffenbacher KE, Iqbal J, Sanger W, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. *Blood*. 2012;119(16):3757-3766.
 37. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA*. 2005;102(43):15545-15550.
 38. Mihailovich M, Bremang M, Spadotto V, et al. miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. *Nat Commun*. 2015;6:8725.
 39. Rapoport AP, Simons-Evelyn M, Chen T, et al. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. *Blood Cells Mol Dis*. 2001;27(3):610-624.
 40. Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. *Blood*. 2013;122(26):4220-4229.
 41. Packard TA, Cambier JC. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. *F1000Prime Rep*. 2013;5:40.
 42. Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity. *Immunology*. 2003;108(3):263-273.
 43. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.
 44. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. *N Engl J Med*. 2013;369(20):1915-1925.
 45. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. *Cell*. 2012;151(1):68-79.
 46. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Mol Cell Biol*. 1999;19(1):1-11.
 47. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. *Genes Dev*. 1999;13(20):2658-2669.
 48. Gu Z, Flemington C, Chittenden T, Zambetti GP. ei24, a p53 response gene involved in growth suppression and apoptosis. *Mol Cell Biol*. 2000;20(1):233-241.
 49. Reed SM, Hagen J, Tompkins VS, Thies K, Quelle FW, Quelle DE. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. *Cell Cycle*. 2014;13(8):1288-1298.
 50. Mraz M, Dolezalova D, Plevova K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. *Blood*. 2012;119(9):2110-2113.
 51. Gao Z, Hsieh CL, Zhou J, Shemshedini L. Zinc Finger 280B regulates sGC α 1 and p53 in prostate cancer cells. *PLoS One*. 2013;8(11):e78766.
 52. Mangum DS, Downie J, Mason CC, et al. VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. *Leukemia*. 2014;28(1):216-220.
 53. Pervez S, Raza MQ, Mirza A, Pal A. Strong BCL2 expression in Burkitt lymphoma is not uncommon in adults. *Indian J Pathol Microbiol*. 2011;54(2):290-293.
 54. Cato MH, Chintalapati SK, Yau IW, Omori SA, Rickert RC. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. *Mol Cell Biol*. 2011;31(1):127-137.
 55. Sawai CM, Freund J, Oh P, et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. *Cancer Cell*. 2012;22(4):452-465.
 56. Husain A, Begum NA, Taniguchi T, Taniguchi H, Kobayashi M, Honjo T. Chromatin remodeler SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability. *Nat Commun*. 2016;7:10549.